Novartis Invests Over $200 Million to Expand Isotope Production Amid Global Shortage
Novartis
Drug Development and Manufacturing
On September 5, according to foreign media reports, to address the global shortage of nuclear components, Novartis has begun establishing a radiopharmaceutical production base in the United States.
The new plant, located in Carlsbad, California, is the company’s third isotope facility following the two production bases in Millburn, New Jersey, and Indianapolis. At the same time, Novartis also plans to further expand the Indianapolis facility. Novartis stated that there is room for further expansion at both new plants.The total investment is expected to exceed 200 million US dollars. It is reported that the qualification and regulatory approval of the new facility is expected to be completed in 2026.
Radiation therapy is a key focus area for Novartis, and the company has invested heavily in global production. Novartis also has radiation therapy facilities in Ivrea, Italy, and Zaragoza, Spain, and a plant in Jiaxing, China, has already broken ground. Earlier this year, Novartis announced thatThe production capacity of radioligand therapy can reach 250,000 doses per year, but global demand still exceeds supply.In June this year, BMS suspended a Phase 3 clinical trial of a drug acquired for $4.1 billion due to an isotope shortage.
Novartis plans to expand its isotope production capacity to the region. Currently, the FDA has approved Novartis' facility in Indianapolis for production. Subsequently, Novartis also intends to build another plant in Japan and will continue to collaborate with external isotope suppliers.
By reporter Miao Miao
Editor: Jiang Yun, Jia Ting
Operation｜Han Jinrui
New Development | Up to $635 Million! Another Bispecific Antibody Successfully Goes Overseas
